SCHEMBL1023939

SCHEMBL1023939

C=CCOC(=O)NC(N)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.60
CACNA1B Q00975 1/20 0.60
APBA1 Q02410 1/20 0.60
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP3A4 P08684 1/20 0.39
TSHR P16473 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CASP1 P29466 4/20 0.35
NPSR1 Q6W5P4 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
RAB9A P51151 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2A1 P68400 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
CRBN Q96SW2 1/20 0.33
GAA P10253 1/20 0.33
FGFR4 P22455 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL729016 0.88 MAPT (0.50) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL7312659 0.85 MAPT (0.50) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL27372531 0.82 MAPT (0.46) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL1076421 0.82 MAPT (0.46) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL2357850 0.80 MAPT (0.44) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL9425493 0.80 MAPT (0.48) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL11336077 0.79 MAPT (0.49) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL7448963 0.79 MAPT (0.45) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL22811355 0.79 MAPT (0.45) MAPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL1586225 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173742-B2 Synthesis of biurets and isocyanates with alkoxysilane functions, formulations containing same and use thereof PERSTORP FRANCE (FR) 2012-05-08 US disclosed
US-20110065957-A1 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF PERSTORP FRANCE (FR) 2011-03-17 US disclosed
US-7875693-B2 reacting hexamethylene diisocyanate with aminopropy/ltrimethoxysilane/3-/ to form intermediate isocyanatoalkylsilane and reacting the isocyanatoalkylsilane with an isocyanate to form a biuret PERSTORP FRANCE (FR) 2011-01-25 US disclosed
US-20070015895-A1 Synthesis of biurets and isocyanates with alkoxysilane functions, formulations containing same and use thereof RHODIA OPERATIONS (FR) 2007-01-18 US disclosed
EP-1117716-B1 OLIGOMERIC AND HIGH-MOLECULAR CONVERSION PRODUCTS OF ALLOPHANIC ACID ESTERS WITH NUCLEOPHILIC COMPOUNDS , AND THE USE THEREOF BASF COATINGS AG (DE) 2004-11-17 EP disclosed
EP-0718290-B1 Carboxyalkyl heterocyclic derivatives NIPPON ZOKI PHARMACEUTICAL CO (JP) 2002-04-17 EP disclosed
EP-1117716-A1 OLIGOMERIC AND HIGH-MOLECULAR CONVERSION PRODUCTS OF ALLOPHANIC ACID ESTERS WITH NUCLEOPHILIC COMPOUNDS AND LOW-MOLECULAR, OLIGOMERIC AND HIGH-MOLECULAR COMPOUNDS WITH ALLOPHANATE SIDE AND/OR TERMINAL GROUPS, AND THE USE THEREOF BASF Coatings AG (DE) 2001-07-25 EP disclosed
WO-2000012578-A1 OLIGOMERIC AND HIGH-MOLECULAR CONVERSION PRODUCTS OF ALLOPHANIC ACID ESTERS WITH NUCLEOPHILIC COMPOUNDS AND LOW-MOLECULAR, OLIGOMERIC AND HIGH-MOLECULAR COMPOUNDS WITH ALLOPHANATE SIDE AND/OR TERMINAL GROUPS, AND THE USE THEREOF BASF COATINGS AG (DE) 2000-03-09 WO disclosed
US-5912261-A ANTIDIABETIC AGENTS NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1999-06-15 US disclosed
EP-0718290-A1 Carboxyalkyl heterocyclic derivatives NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1996-06-26 EP disclosed
US-4520147-A TRIAZOLIDINE-3,5-DIONES; SELF-EXTINQUISHING BAYER AKTIENGESELLSCHAFT (DE) 1985-05-28 US disclosed
US-4396736-A TRIAZOLIDINE-3,5-DIONES OR DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1983-08-02 US disclosed
EP-0003870-A1 Aqueous polymer resin emulsions and water-based paints and coatings containing such emulsions AIR PRODUCTS AND CHEMICALS, INC. (US) 1979-09-05 EP disclosed
US-3933846-A FUNGICIDES, OVICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065957-A1 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF THEM6, INMT, BCAT2 MAPT 363/4885CACNA1B 3708/4885APBA1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.